Physician profile
Jay M Taylor
NPI 1689641300
$73,471.29
in general payments reported to CMS, 2019-2025
13 companies · $49K in 2025
The $49K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $159 · 2024: $24K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $73K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $72,884.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $72,884.46 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $131.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $123.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $113.44 | 2019 | |
| Amgen INC. | $40.62 | 2019-2020 | |
| Novo Nordisk INC | $39.33 | 2019 | |
| Sanofi Pasteur INC. | $34.76 | 2019-2020 | |
| Pfizer INC. | $30.10 | 2019-2020 | |
| Radius Health, INC. | $23.70 | 2019 | |
| Glaxosmithkline, LLC. | $13.99 | 2019 | |
| Lilly USA, LLC | $12.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.